Cipla to Present at the 40th Annual J.P. Morgan Healthcare Conference Kumar Jeetendra | January 12, 2022 India; January 12, 2022: Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as “Cipla” today announced that it will participate at the 40th Annual J.P. Morgan Healthcare Conference, which is the largest healthcare investment symposium in the industry. Mr. Umang Vohra, MD and Global CEO, Cipla, will virtually present a corporate overview of the …
Indica Labs’ HALO AP® platform achieves CE-IVD certification for use in primary diagnosis Kumar Jeetendra | January 10, 2022 Albuquerque, NM, 10 January, 2022 – Life Science Newswire – Indica Labs, a leading provider of computational pathology software and services, is proud to announce that following ISO13485 certification, HALO AP® has received a CE Mark for use in primary diagnosis within the European Economic Area, Switzerland, and the UK. The HALO AP platform was …
Alembic Pharmaceuticals receives USFDA Tentative Approval for Dronedarone Tablets USP, 400 mg. Kumar Jeetendra | January 10, 2022 10th January, 2022, Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Dronedarone Tablets USP, 400 mg. The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Multaq Tablets, 400 mg, …
Alembic Pharmaceuticals receives USFDA Tentative Approval for Vortioxetine Tablets 5 mg, 10 mg, 15 mg, and 20 mg. Kumar Jeetendra | January 7, 2022 7th January, 2022, Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Vortioxetine Tablets 5 mg, 10 mg, 15 mg, and 20 mg. The tentatively approved ANDA is therapeutically equivalent to the reference listed drug …
Alembic Pharmaceuticals receives USFDA Final Approval for Entacapone Tablets USP, 200 mg. Kumar Jeetendra | January 6, 2022 6th January, 2022, Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Entacapone Tablets USP, 200 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Comtan Tablets, 200 mg, of …
Alembic Pharmaceuticals receives USFDA Final Approval for Doxycycline Hyclate Delayed-Release Tablets USP, 75 mg, 100 mg, 150 mg, and 200 mg. Kumar Jeetendra | January 4, 2022 4th January, 2022, Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxycycline Hyclate Delayed-Release Tablets USP, 75 mg, 100 mg, 150 mg, and 200 mg. The approved ANDA is therapeutically equivalent to the reference …
Emcure Pharma to launch oral Covid-19 drug in a week Kumar Jeetendra | January 2, 2022 Emcure Pharmaceuticals Ltd (EPL) reported that it received an emergency Use Authorisation (EUA) approval from the Drug Controller General of India for the introduction of Molnupiravir the oral anti-viral that is under investigation, to treat mild COVID-19. EPL plans to launch this drug with the name Lizuvira on India. Indian market. “As the need for …
Cipla receives Emergency Use Authorisation (EUA) to launch oral anti-viral drug Cipmolnu® (Molnupiravir 200 mg) in India for treatment of adult patients with COVID-19, with SpO2>93% and who have high risk of progression of the disease including hospitalization or death. Kumar Jeetendra | December 28, 2021 Mumbai, India; December 28, 2021: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) announced today that it has been granted Emergency Use Authorisation(EUA) permission by the Drug Controller General of India (DCGI) for the launch of Molnupiravir in the country. Cipla plans to launch Molnupiravir under the brand name Cipmolnu®. …
New drug Molnupiravir can be the solution for our fight against COVID-19 Kumar Jeetendra | December 28, 2021 Mumbai, 28th December 2021: As countries prepare themselves to fight a possible ‘next wave’. The new variant – Omicron has been making headline and a surge in covid 19 cases are evident. According to a study based on population-level evidence, the recently identified Omicron variant of SARS-CoV-2 is associated with a substantial ability to evade …
Cipla Receives Final Approval for Lanreotide Injection Kumar Jeetendra | December 19, 2021 Mumbai, India, & New Jersey, USA: December 19, 2021: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”)and its subsidiary Cipla USA, Inc., (hereafter referred to as “Cipla”), today announced that it has received final approval for its Lanreotide Injection, from the United States Food and Drug Administration (US FDA). The …
Cipla acquires stake in Clean Max Auriga Power LLP; progresses towards championing its ESG agenda Kumar Jeetendra | December 16, 2021 Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) announced today that it has acquired up to 33% of partnership interest in Clean Max Auriga Power LLP (Limited Liability Partnership). This agreement is in line with the Company’s commitment to enhance the share of renewable power source in its operation and …
Inceptua receives approval of marketing authorization transfer of Apealea® (paclitaxel micellar) for the treatment of ovarian cancer Kumar Jeetendra | December 14, 2021 LUXEMBOURG – 14 December 2021 – Life Science Newswire – Inceptua Group – pharmaceutical company and service partner – today announces that the European Commission (EC) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the transfer of the marketing authorization for Apealea® (paclitaxel micellar) from Oasmia Pharmaceutical AB to Inceptua AB. …
